BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Following the watershed approval of Iovance’s Lifileucel\, all
  eyes are now on TIL therapies as the up-and-coming major therapeutic ave
 nue for solid tumor treatment. Introducing the 6th Annual TIL Therapies S
 ummit! With 30+ expert speakers\, 12 new speaker companies\, 2 brand-new 
 content-filled tracks and 2 brand-new interactive workshops\, you won't w
 ant to miss out! As the only meeting placing the entire spotlight on TIL 
 drug development\, this summit will unveil the latest to share clinical u
 pdates\, next-generation candidates\, manufacturing innovations\, and ass
 ay characterizations to turbocharge development of the next wave of TIL t
 herapies. Hear from TIL industry leaders like Iovance\, MD Anderson Cance
 r Center\, Obsidian Therapeutics\, Steven Rosenberg’s group from the Nati
 onal Institute of Health and more\, as they share ground-breaking TIL dis
 coveries from R&amp\;D to commercialization. Join us in October to capita
 lize on this golden opportunity to ensure you and your entire team stay a
 head of the TIL wave!\n
DTEND:20241024T170000
DTSTAMP:20260512T232950Z
DTSTART:20241022T090000
LOCATION:The Colonnade\, 120 Huntington Ave\, Boston\, MA\, 02116\,
SEQUENCE:0
SUMMARY:Following the watershed approval of Iovance’s Lifileucel\, all eye
 s are now on TIL therapies as the up-and-coming major therapeutic avenue 
 for solid...
UID:cd1c7efd-e1d0-4041-98f4-fcf7c91d67f8
END:VEVENT
END:VCALENDAR